Press Room

Find news and updates from PhRMA, representing the country’s leading biopharmaceutical research companies. Our members are committed to finding tomorrow’s cures and treatments for some of the most serious diseases such as cancer, Alzheimer’s disease, cystic fibrosis and Parkinson’s.

Latest News from PhRMA

More than 85 medicines in development for Alzheimer’s disease

September 21, 2017

There are 87 potential new treatments in clinical trials for Alzheimer’s disease.

Read More

The journey to better health care requires a holistic view

September 18, 2017

The journey to better health care requires a holistic view.

Read More

What they are saying: Study on cancer R&D costs is not an accurate representation of marketplace

September 12, 2017

There's more to research and development costs of cancer medicines than this recent study shows.

Read More

PhRMA Statement on Commissioner Scott Gottlieb’s Address to the Regulatory Affairs Professionals Society 2017 Regulatory Conference

September 12, 2017

PhRMA director, Public Affairs, Andrew Powaleny issued a statement following U.S. FDA Commissioner Scott Gottlieb’s address to the Regulatory Affairs Professionals Society 2017 Regulatory Conference.

Read More

Medicare Monday: Medicare Part D by the numbers

September 11, 2017

Key stats about Medicare Part D.

Read More

How biopharmaceutical collaboration is driving a new era of medicine

September 7, 2017

Biopharmaceutical innovation and technological advancements are transforming how we research and develop new medicines to benefit patients.

Read More

Protect Your Health: Important Disaster Preparedness Tips for Harvey and Irma

September 6, 2017

Hurricane Irma is poised to make a hit on health care infrastructure. That’s why it’s crucial to create a disaster preparedness plan for your health care needs.

Read More

PhRMA and BIO Initiate Litigation to Challenge Unconstitutional Provisions of Nevada’s SB 539

September 1, 2017

Today, PhRMA and BIO initiated litigation challenging provisions of SB 539, a Nevada law that would violate patent rights and negate trade secret protection for designated diabetes medicines in a way that would harm patients and chill future biomedical innovation.

Read More

Helping those affected by Hurricane Harvey and Irma

August 31, 2017

Helping those affected by Hurricane Harvey and Irma

Read More

SB 17 doesn’t address pressing prescription drug transparency issues for CA voters

August 30, 2017

Does the promise of SB 17 align with the needs of Californians?

Read More
prev 1 2 3 4 5 6 next